{"name":"Beam Therapeutics Inc.","slug":"beam","ticker":"BEAM","exchange":"NASDAQ","domain":"beamtx.com","description":"Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rar","hq":"Cambridge, MA","founded":0,"employees":"522","ceo":"John Evans","sector":"Biotech — Gene Editing","stockPrice":29.59,"stockChange":-2.26,"stockChangePercent":-7.1,"marketCap":"$3.0B","metrics":{"revenue":164011008,"revenueGrowth":324.9,"grossMargin":-146.9,"rdSpend":0,"netIncome":-65980000,"cash":1211651968,"dividendYield":0,"peRatio":-6.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"BEAM-101 patent cliff ($0.0B at risk)","drug":"BEAM-101","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"BEAM-102 patent cliff ($0.0B at risk)","drug":"BEAM-102","type":"patent_expiry","sentiment":"negative"},{"date":"2036-06-01","label":"BEAM-201 patent cliff ($0.0B at risk)","drug":"BEAM-201","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Beam Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for BEAM-101","summary":"Beam Therapeutics announced that the FDA has cleared the IND application for BEAM-101, enabling the company to initiate a Phase 1 clinical trial.","drugName":"BEAM-101","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Beam Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Beam Therapeutics reported its third-quarter 2023 financial results, with a net loss of $43.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Beam Therapeutics Announces Collaboration with Pfizer to Develop Gene Editing Therapies","summary":"Beam Therapeutics announced a collaboration with Pfizer to develop gene editing therapies for various diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPcUNUUXNwaHV4WS1Za1FaWE5kOWREbG8yWDU3TzRJQVR1Z0JBOElqbXhUcDlGUXJLWmNWLTJ4VWNMV3lRTmRVN1JfUlJ2Wnp2ODVXZTZ4c2kyNzlxdHJyZXFibnV5TEo1bVZXTTZoNUYwTGVLWVFCVC1jbGVxXy04WjlKLWxjTF82M1pkLU1vdHBRNzlKWkVPOE9NMjF4VTZsM2p5NklVT2JaYUlvdm5oNzQwRkc5Qkw0aVdZTzBTRlQ5QjZyNS1yemFmR09FejZReDh6OG1hMkpFazRLMDZzbTY1WmZpQ01xMV9td3JFSjhmdndIemRBRWpPLXhGbTBNX1NIc29BT1dBa2dDMEdJbHNvZ3g2QWstdFptU2RMX05jYklzTVdEWDVLdFZQYk5UX2lJMkhWNkpJMGxD?oc=5","date":"2026-03-27","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRGVFYXhTUHk5OGFCOVNxUklCUWFWOWYydFZKZzBCTzFkOU82aU1OdGw3Ui1jT3NrZ0NDNENsZUhvY2UyQW02dGdsMHdFY3ZlV1VvNXlfeTViYTVJWXljZWdmRS02ZnhQNGF5dXFWeTY2VVN6M2lKYzU5dFJQYmdDUUFncnM5Q1Bxd2NkQVRhbkNqQ3hmQVZRbzFjWXd4aURVVC01NFJEdjQyMUN6MDIyM2NfNW4yc240U3d1ZA?oc=5","date":"2026-03-26","type":"trial","source":"TradingView","summary":"BEAM Eyes Global Expansion of AATD Study After Strong Early Data - TradingView","headline":"BEAM Eyes Global Expansion of AATD Study After Strong Early Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNSUNkT2dHVnlCOGhDODgycHNMYXktSzRfYXdwUHVvZU02dDhEUzJTMmNLbWtUM3BzQTVpR3VFU2FzMjJLcW1VMHlCS1MwaGtJU0ZIX3lvUnlxRE5Oa09GdmtPNkMyalQ4Z0lSNWtDYkhILUdFR2syOXBYQ3RWNldJUVpPYk1CdlJqZkNXZWIyQ0cySEhkR1dsRTROUFJYd2ZWMGpqTER4blRzWWJoN3ZFMTN1cHlvU1llN2J2eVY0Uy10VThQZi1peGRIak1YcmZxRlE?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPSjN2bE1fTHVBQUFtQnozZG1HeTdzNzFyYW9ON0RjcERHOGM0TE13MTBSZFJqajF2RHJPTnVWcXJWc0ROX25rSWhpQ2s4WW9ZcXRHZF9QZzZKQkZqcEJZT2JrdUVyLWxRRW4tNEJTNXdFdnc4eWdGSjlVSm5DQ2xyWGNFYVNxMTh0MWFsSDlydXRxcm5hdGVRVDhPalhLLWZwZ3pDUlZn?oc=5","date":"2026-03-17","type":"deal","source":"The Motley Fool","summary":"Best CRISPR Companies to Buy in 2026 and How to Invest in Them - The Motley Fool","headline":"Best CRISPR Companies to Buy in 2026 and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQXzZrcFdWMTdHQXdQYWRZWG11ZGtpMjZ0dUlwN05Yb0dwalN1ai1LYWZzcVZHT0tNU0FnNzVhcWJ0QlljRl9zYlA1MVNLMUlKc2NsMUt2azRqcWRLQ3NkdWVnZ195REdKV1h0R1BJWkpNSFNCSWRtNF8zZGtXM0ROQUxwUXhnOWEtN3VCQ0VFanozNHlxYW9TMFp6N0VGUQ?oc=5","date":"2026-02-27","type":"pipeline","source":"Seeking Alpha","summary":"Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM) - Seeking Alpha","headline":"Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1vN0ZSV0Y5Nnd2a1NBZVZSeFZNZU1Uakstamd3eDhnZjVkRG84cWlPRGphRm5UTnYyNWd0cDhmTVJZMHNnTDNSQVduRHFqeVF0WnBIdDNJN1JwMDVOaWRyWlBuRkpyOFd5Tl84M2VIYlNvZHlfSGFLRQ?oc=5","date":"2026-02-27","type":"deal","source":"U.S. News Money","summary":"7 Top Gene-Editing Stocks to Buy - U.S. News Money","headline":"7 Top Gene-Editing Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPSVNBdHRZVndjX0pLbHRwOGRhT2pOeS01c2otQThkTzByR2M4VUo3enV4MWh2M2tuU2xYcTBhZU1LMml0elJWNTlEX3RkeHVLVmU4WlZHd3BiUWp4bm5FR2xDXzR4WG9SdVpGQW1rekZ3LWhFNmlRUDZYNmNkZkw1SU14clAxSDA0T1JhSmlWOGN2Zi1nSVkzdkp4emJOUGVBQTFEaA?oc=5","date":"2026-02-26","type":"pipeline","source":"BioSpace","summary":"Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy - BioSpace","headline":"Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQbGxQNXJXb1RjUjl5WmhZRzYtbUNQWFozV25WNDVqNG1FLU9JRF80UnowZ1BBMm5pTDh2a0tMMzlSOGNRY3hFVEFvb2w4Z2Q2UWc0WWxEbXdmOGdGSUJFSXQxNHFhMlRZXzUxR3hVRFZGNUY1aE44Z2dBdm8xSDRFNEdJV0xCenJnQ25HWU13?oc=5","date":"2026-02-25","type":"pipeline","source":"Yahoo Finance","summary":"Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing - Yahoo Finance","headline":"Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOcFZZRklodmRSaWpkaDBMQlhPcTJuYlJyX2NTVnVWdHBibjJwalJYQXdQUnZUYmJSVnZNd3dvREZFUjZZOVZsdDJkM2M1NjVEeTN1YkwzZ2kwMDRabEEzS0FySEVTMTJITWFlOVVxc0dEWnlPczBKMTc2UlptMlhKZmc0dHI5NTJoUHYzUEU5a1RkRnZURTFyd243UXJTWEVhTEd5eXFrYS1KaFI0Nl9lTU53enhFRlBLenE4R25ONmMtRGpCb3NqbHBZZw?oc=5","date":"2026-02-24","type":"pipeline","source":"Sixth Street","summary":"Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - Sixth Street","headline":"Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPdk96Wi1oVjZWRnRCUG1WN0c4UkdFaGRsOVFyYURnSVJnREJ0Vk0yajVZX1RlRFcwZXp4UFhtcGNFWW1IMzV6d2tzQ3pKTHM0Tm5yaGtjcjFuX20ydVM1SEFMeHFsMEktY0EwN05YTnluU1QxUHRYR0VLcGI0MXBNbHAtSTl5WElOMFhVYXZ1Zw?oc=5","date":"2026-02-24","type":"trial","source":"Endpoints News","summary":"Beam Therapeutics’ new PKU program; Protara’s bladder cancer data - Endpoints News","headline":"Beam Therapeutics’ new PKU program; Protara’s bladder cancer data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNaFg2d09wY2Z3Zm1ISFNzVWd6dG5XZld3eTRPbGhYWDhnNjliNWdVZWlYMHA1Wk1FN1Z6Z2lOVUJwQmhkWGo2MHR4TVRBRm8zNVNWc1IyX1F1Q0ZOb1ZmN21NaUpUblh2VVA0aUY1YW5QVDJxZzFfM3oyRmdrTGdnSzUwVUpNMVROT2dnVkNtT2NfTWR1d3ByUUpnTVlYdUdjVkJQY3laMA?oc=5","date":"2026-01-21","type":"pipeline","source":"Fierce Biotech","summary":"Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery - Fierce Biotech","headline":"Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOclEtbDVOY0hUNEgxUHR4RTFZcDFvQmdqMk1aUFdHeWxud25RUGpENW5ZUktEeWxCTEVkZDM3OVJxZWZLc3pWcXc0a2J2ZXhGMi1YREtYT1RuYW4xNEtfb09Da1R1T0pLTEt3c25NU2pPT0Z4M2tXQTJSaTZ6c2Uxc2V2QW5UQ1E?oc=5","date":"2025-12-31","type":"pipeline","source":"Yahoo Finance","summary":"Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - Yahoo Finance","headline":"Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?","sentiment":"neutral"}],"patents":[{"drugName":"BEAM-101","drugSlug":"ctx001","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"BEAM-102","drugSlug":"ctx002","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0},{"drugName":"BEAM-201","drugSlug":"ctx003","patentNumber":"","type":"Patent Cliff","expiryDate":"2036-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Sickle Cell Disease","Beta-Thalassemia"],"financials":{"source":"yahoo_finance","revenue":139743000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":139743000},{"period":"2024-12-31","value":63518000},{"period":"2023-12-31","value":377709000},{"period":"2022-12-31","value":60920000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":409618000,"rdSpendHistory":[{"period":"2025-12-31","value":409618000},{"period":"2024-12-31","value":367561000},{"period":"2023-12-31","value":437381000},{"period":"2022-12-31","value":311594000}],"sgaSpend":113818000,"operatingIncome":-383693000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-383693000},{"period":"2024-12-31","value":-415568000},{"period":"2023-12-31","value":-176485000},{"period":"2022-12-31","value":-338479000}],"netIncome":-79992000,"netIncomeHistory":[{"period":"2025-12-31","value":-79992000},{"period":"2024-12-31","value":-376742000},{"period":"2023-12-31","value":-132527000},{"period":"2022-12-31","value":-289088000}],"eps":-0.81,"epsHistory":[{"period":"2025-12-31","value":-0.81},{"period":"2024-12-31","value":-4.58},{"period":"2023-12-31","value":-1.72},{"period":"2022-12-31","value":-4.13}],"cash":294944000,"cashHistory":[{"period":"2025-12-31","value":294944000},{"period":"2024-12-31","value":281967000},{"period":"2023-12-31","value":435895000},{"period":"2022-12-31","value":232767000}],"totalAssets":1481177000,"totalLiabilities":242819000,"totalDebt":154123000,"equity":1238358000,"operatingCashflow":-345102000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-345102000},{"period":"2024-12-31","value":-347246000},{"period":"2023-12-31","value":-149195000},{"period":"2022-12-31","value":22527000}],"capex":-14946000,"capexHistory":[{"period":"2025-12-31","value":-14946000},{"period":"2024-12-31","value":-8946000},{"period":"2023-12-31","value":-33732000},{"period":"2022-12-31","value":-48951000}],"freeCashflow":-360048000,"dividendsPaid":null,"buybacks":null,"employees":522,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":34429000,"ebit":-107215000,"ebitda":-101610000,"period":"2026-03-31","revenue":31738000,"epsBasic":-0.91,"netIncome":-94318000,"rdExpense":104524000,"epsDiluted":-0.91,"grossProfit":null,"operatingIncome":-107215000},{"sga":32279000,"ebit":-17445000,"ebitda":-11777000,"period":"2025-12-31","revenue":114109000,"epsBasic":2.37,"netIncome":244297000,"rdExpense":99275000,"epsDiluted":2.33,"grossProfit":null,"operatingIncome":-17445000},{"sga":26740000,"ebit":-126811000,"ebitda":-121251000,"period":"2025-09-30","revenue":9698000,"epsBasic":-1.1,"netIncome":-112728000,"rdExpense":109769000,"epsDiluted":-1.1,"grossProfit":null,"operatingIncome":-126811000},{"sga":26859000,"ebit":-120151000,"ebitda":-114613000,"period":"2025-06-30","revenue":8466000,"epsBasic":-1,"netIncome":-102291000,"rdExpense":101758000,"epsDiluted":-1,"grossProfit":null,"operatingIncome":-120151000},{"sga":27940000,"ebit":-119286000,"ebitda":-113758000,"period":"2025-03-31","revenue":7470000,"epsBasic":-1.23,"netIncome":-108330000,"rdExpense":98816000,"epsDiluted":-1.23,"grossProfit":null,"operatingIncome":-119286000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":29.59,"previousClose":31.85,"fiftyTwoWeekHigh":36.44,"fiftyTwoWeekLow":15.35,"fiftyTwoWeekRange":"15.35 - 36.44","fiftyDayAverage":27.62,"twoHundredDayAverage":25.44,"beta":2.26,"enterpriseValue":2209412352,"forwardPE":-6.1,"priceToBook":2.53,"priceToSales":18.56,"enterpriseToRevenue":13.47,"enterpriseToEbitda":-6.33,"pegRatio":0,"ebitda":-349251008,"ebitdaMargin":-212.9,"freeCashflow":-233555744,"operatingCashflow":-369731008,"totalDebt":250822000,"debtToEquity":21.5,"currentRatio":16.99,"returnOnAssets":-15.8,"returnOnEquity":-5.8,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":15,"targetMeanPrice":51.13,"targetHighPrice":80,"targetLowPrice":26,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.4,"institutionHeldPercent":104.2,"sharesOutstanding":102879214,"floatShares":88045147,"sharesShort":20936705,"shortRatio":9.71,"shortPercentOfFloat":20.3,"epsTrailing":-0.49,"epsForward":-4.82,"revenuePerShare":1.6,"bookValue":11.71,"officers":[{"age":47,"name":"Mr. John M. Evans M.B.A.","title":"CEO & Director"},{"age":56,"name":"Dr. Giuseppe  Ciaramella Ph.D.","title":"President"},{"age":47,"name":"Mr. Sravan Kumar Emany","title":"Chief Financial Officer"},{"age":59,"name":"Dr. Christine P. Bellon J.D., Ph.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":60,"name":"Dr. Amy  Simon M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Feng  Zhang Ph.D.","title":"Co-Founder"},{"age":null,"name":"Dr. David R. Liu Ph.D.","title":"Co-Founder"},{"age":null,"name":"Dr. J. Keith Joung M.D., Ph.D.","title":"Co-Founder"}],"industry":"Biotechnology","irWebsite":"","website":"https://beamtx.com","phone":"857 327 8775"}}